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Introduction
DNA-dependent protein kinase catalytic subunit (DNAPKcs), a serine threonine kinase belonging to the PIKK family (phosphoinositide 3-kinase-like-family of protein kinase), is an essential component of the non-homologous end-joining (NHEJ) DNA repair pathway [1] [2] [3] [4] [5] [6] . NHEJ is central to the repair of DNA double-strand breaks (DSBs) that may be generated throughout the cell cycle. DNAPKcs is recruited to the sites of DSBs by the Ku70/Ku80 heterodimer which then leads to its auto-phosphorylation at Ser2056, resulting in a conformational change that promotes the DSB repair function of DNA-PKcs in cells. In addition, phosphorylation at Thr2609 by ATM (ataxia telangiectasia mutated) or ATR (ataxia telangiectasiaRad3-related) kinases also regulates the biological functions of DNA-PKcs [1] [2] [3] [4] [5] [6] . Besides an essential role in NHEJ, DNA-PKcs may be involved in cell cycle control, telomere maintenance, transcriptional regulation and p53 dependent apoptosis in cells [1] [2] [3] [4] [5] [6] .
DNA-PKcs deficiency results in severe combined immunodeficiency (SCID) in mammals [7] . The role of DNA-PKcs in carcinogenesis, however, is less well characterised. Single nucleotide polymorphisms in the DNAPKcs gene may be associated with increased risk of bladder [8] and hepatocellular cancer [9] development. In lung cancers, similarly, polymorphisms in the DNA-PKcs gene appear to confer altered cancer susceptibility [10] . Somatic mutations in the DNA-PKcs gene have been described in breast and pancreatic cancers [11] . DNA-PKcs activity appears to be lower in patients with cancer compared to normal controls, implying a role for impaired DNA-PKcs in cancer risk and development. Interestingly, in established human tumours, the situation is far more complex. In tumours such as nasopharyngeal carcinoma, oesophageal cancer, colorectal cancer and lymphoid malignancies, DNA-PKcs is overexpressed and associated with poor prognosis. On the other hand, in gastric and ovarian cancers, low expression of DNA-PKcs is linked to adverse outcomes in patients (reviewed in [12] ). A large body of pre-clinical cancer cell lines or xenograft model-based studies suggests that DNA-PKcs down-regulation or inhibition by small molecule inhibitors is associated with sensitization to chemotherapy and radiotherapy [12] [13] [14] 15] .
The clinicopathological significance of DNA-PKcs expression in breast cancer is unknown. Our hypothesis is that altered DNA-PKcs expression may be associated with aggressive tumour biology and adversely impact upon clinical outcomes. In the current study, we have investigated DNA-PKcs protein as well as mRNA expression in large cohorts of primary breast cancers. We demonstrate that low DNA-PKcs expression is associated with an aggressive phenotype and poor clinical outcome in patients.
Methods

Patients
The study was performed in a consecutive series of 1,650 patients with primary invasive breast carcinoma, who were diagnosed from 1986 to 1999 and entered into the Nottingham Tenovus Primary Breast Carcinoma series. Patient demographics are summarised in supplementary Table S1 . This is a well-characterised series of patients with longterm follow-up that has been investigated in a wide range of biomarker studies. All patients were treated in a uniform way in a single institution with standard surgery (mastectomy or wide local excision) with radiotherapy. Prior to 1989, patients did not receive systemic adjuvant treatment (AT). After 1989, AT was scheduled based on prognostic and predictive factor status, including Nottingham Prognostic Index (NPI), oestrogen receptor-a (ER-a) status and menopausal status. Patients with NPI scores of \3.4 (low risk) did not receive AT. In pre-menopausal patients with NPI scores of C3.4 (high risk), classical Cyclophosphamide, Methotrexate and 5-Flurouracil (CMF) chemotherapy was given; patients with ER-a positive tumours were also offered endocrine therapy. Postmenopausal patients with NPI scores of C3.4 and ER-a positivity were offered endocrine therapy, while ER-a negative patients received classical CMF chemotherapy. Median follow-up was 111 months (range 1-233 months). Survival data, including overall survival, disease-free survival (DFS) and development of loco-regional and distant metastases (DM), were maintained on a prospective basis. DFS was defined as the number of months from diagnosis to the occurrence of local recurrence, local lymph node (LN) relapse or DM relapse. Breast cancer-specific survival (BCSS) was defined as the number of months from diagnosis to the occurrence of breast cancer-related death. Local recurrence-free survival (LRS) was defined as the number of months from diagnosis to the occurrence of local recurrence. DM-free survival was defined as the number of months from diagnosis to the occurrence of DM relapse. Survival was censored if the patient was still alive at the time of analysis, lost to follow-up or died from other causes.
Tumour Marker Prognostic Studies (REMARK) criteria, recommended by McShane et al. [16] , were followed throughout this study. Ethical approval was obtained from the Nottingham Research Ethics Committee (C202313).
Construction of tissue microarray (TMA)
TMAs were constructed. Area-specialised histopathologists identified and marked formalin-fixed paraffin-embedded tissue blocks containing tumour tissue on haematoxylin and eosin-stained slides. Two replicate 0.6 mm cores from the centre and periphery of the tumours were taken and arrayed into a recipient paraffin block using a tissue puncher/arrayer (Beecher Instruments, Silver Spring, MD, USA). Four micron sections of the tissue array block were cut and placed on Superfrost Plus slides for immunohistochemical staining.
Immunohistochemistry (IHC)
The TMAs were immunohistochemically profiled for DNAPKcs and other biological antibodies (Supplementary Table  S2 ) as previously described [17] [18] [19] . Immunohistochemical staining was performed using the Thermo Scientific Shandon Sequenza chamber system (REF: 72110017), in combination with the Novolink Max Polymer Detection System (RE7280-K: 1,250 tests) and the Leica Bond Primary Antibody Diluent (AR9352), each used according to the manufacturer's instructions (Leica Microsystems). The tissue slides were deparaffinised with xylene and then rehydrated through five decreasing concentrations of alcohol (100, 90, 70, 50 and 30 %) for 2 min each. Pre-treatment antigen retrieval was performed on the TMA sections using sodium citrate buffer (pH 6.0), heated for 20 min at 95°C in a microwave (Whirpool JT359 Jet Chef 1000 W). The slides were incubated for 1 h with the primary mouse monoclonal anti-DNA PKcs antibody clone 3H6 (ab110034, Abcam, Cambridge, UK) at a dilution of 1:1,000.
To validate the use of TMAs for immunophenotyping, full-face sections of 40 cases were stained, and protein expression levels of DNA-PKcs antibodies were compared. The concordance between TMAs and full-face sections was excellent (k = 0.8). Positive and negative (by omission of the primary antibody and IgG-matched serum) controls were included in each run.
Evaluation of immunohistochemical staining
The tumour cores were evaluated by specialist pathologists and oncologists blinded to the clinicopathological characteristics of patients. Whole field inspection of the core was scored, and intensities of nuclear staining were grouped as follows: 0 = no staining, 1 = weak staining, 2 = moderate staining and 3 = strong staining. The percentage of each category was estimated (0-100 %). H-score (range 0-300) was calculated by multiplying intensity of staining and percentage staining. H-score in a range of 0-300 was generated. The mean H-score of 260 was taken as the cutoff, and high DNA-PKcs expression was classed as H-score of [260. Not all cores within the TMA were suitable for IHC analysis as some cores were missing or lacked tumour. HER2 expression was assessed according to the new ASCO/CAP guidelines using IHC and chromogenic in situ hybridisation (CISH) [20] .
Statistical analyses
Data analysis was performed using SPSS (SPSS, version 17 Chicago, IL), where appropriate Pearson's v 2 , Fisher's exact, v 2 for trend, Student's t and ANOVAs one-way tests were performed using SPSS software (SPSS, version16 Chicago, IL). Cumulative survival probabilities were estimated using the Kaplan-Meier method. Differences between survival rates were tested for significance using the log-rank test. Multivariate analysis for survival was performed using the Cox hazard model. The proportional hazards assumption was tested using standard log-log plots. Each variable was assessed in univariate analysis as a continuous and categorical variable, and the two models were compared using an appropriate likelihood ratio test. Hazard ratios (HR) and 95 % confidence intervals (95 % CI) were estimated for each variable. All tests were two-sided with a 95 % CI. p values for each test were adjusted with Benjamini and Hochberg multiple p value adjustment, and an adjusted p value of\0.05 was considered significant.
Breast cancer cell lines and Western blot analysis MCF-7, MDA-MB-231 and MDA-MB-436 breast cancer cell lines were purchased from ATCC and grown in RPMI medium supplemented with 10 % FBS and 1 % penicillin/ streptomycin. Western blot analysis was performed as described previously [21] .
DNA-PKcs mRNA expression
The METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) cohort comprising a cohort of 1,980 breast cancer samples [22] was evaluated for DNAPKcs mRNA expression. Patient demographics are summarised in supplementary Table S3 of supporting information. ER-positive and/or lymphnode-negative patients did not receive adjuvant chemotherapy. ER-negative and/or lymphnode-positive patients received adjuvant chemotherapy. RNA was extracted from fresh frozen tumours and subjected to transcriptional profiling on the Illumina HT-12 v3 platform. The data were pre-processed and normalised as described previously [22] . DNA-PKcs expression was investigated in this data set. X-tile (version 3.6.1, Yale University, USA) was used to identify a cut-off in gene expression values to divide the population into high/low subgroups prior to Kaplan-Meier Survival analysis.
Results
DNA-PKcs protein expression in breast cancer (whole cohort)
As shown in Fig. 1a , robust expression of DNA-PKcs was evident in MCF-7, MDA-MB-231 and MDA-MB-436 breast cancer cells implying that the antibody used in the current study was robust in detecting DNA-PKcs protein expression. We then proceeded to immunohistochemical investigation. A total of 1,161 tumours were suitable for DNA-PKcs protein expression analysis (Table 1) . 404/1,161 (34.8 %) had low DNA-PKcs expression compared to 757/1,161 (65.2 %) tumours that had high DNA-PKcs expression (Fig. 1a) . Low DNA-PKcs expression was associated with higher tumour grade (p = 0.001), higher mitotic index (p \ 0.000001), tumour de-differentiation (p = 0.008) and tumour type (p = 0.031) ( Table 1) . ERnegative tumours were more likely to have low DNA-PKcs expression (p = 0.021), as were AR-negative tumours (p = 0.00001). DNA-PKcs expression was also associated with cytokeratin 18 (CK18) (p = 0.007) and cytokeratin 19 (CK19) (p = 0.002). Low p21 and low TOP2A were likely in low DNA-PKcs expressing tumours (p \ 0.05). The absence of BRCA1, low XRCC1, low SMUG1, low APE1, low FEN1 and low Polb was also more likely associated with low DNA-PKcs expression in tumours (p \ 0.05).
Low DNA-PKcs expression was significantly associated with worse BCSS (p = 006) and DFS (p \ 0.0001) (Fig. 1b, c) . On multivariate cox regression analysis, DNAPKcs remained independently associated with BCSS (p \ 0.001) and DFS (p \ 0.001), alongside tumour stage, grade and size (Table 2) .
Taken together, the data suggest that low DNA-PKcs may be associated with aggressive breast cancer DNA-PKcs protein expression in ER-positive breast cancer A total of 835 tumours were suitable for analysis. 272/835 of patients (32.5 %) with ER-positive breast cancer were classified as having low DNA-PKcs expression. Univariate associations between DNA-PKcs expression and clinicopathological variables are shown in Table 3 . Low DNA-PKcs expression was associated higher tumour grade (p = 0.021), higher mitotic index (p = 0.013), tumour de-differentiation (p = 0.011) and tumour type (p = 0.018). AR-tumours were more likely to have low DNA-PKcs expression (p = 0.001). Low DNA-PKcs expression was also associated low TOP2A (p = 0.002). DNA repair protein levels associated with low DNA-PKcs expression included the absence of BRCA1 (p = 0.045), XRCC1 (p \ 0.0001), SMUG1 (p \ 0.0001), APE1 (p \ 0.0001), FEN1 (p = 0.001) and polb (p \ 0.0001) ( Table 3) . Low DNA-PKcs expression was significantly associated with worse BCSS (p = 0.027) (Fig. 1d) and DFS (p \ 0.01) (Fig. 1e) . In ER?/NPI [3. DNA-PKcs expression remains significantly associated with worse BCSS) (p = 0.048) (Fig. 1f) and DFS (p = 0.016, Fig. 1g ). In ER?/NPI [3.4 high-risk breast cancer who did not receive endocrine therapy, low DNA-PKcs did not significantly influence BCSS although remained significant for DFS (p = 0.044) (Fig. 2a, b) .
DNA-PKcs protein expression in ER-negative breast cancer
A total of 311 tumours were suitable for analysis. 122/311 of patients (39.2 %) with ER-negative breast cancer were classified as having low DNA-PKcs expression. Univariate associations between DNA-PKcs expression and clinicopathological variables are shown in Table 4 . Low DNAPKcs expression was associated higher mitotic index (p = 0.002), AR-(p = 0.038), low XRCC1 (p = 0.003), low APE1 (p \ 0.0001), low polb (p = 0.017) and low p21 (p = 0.01). Low DNA-Pkcs did not influence survival in ER-negative tumours (Fig. 2c, d ). (Fig. 3a) . However, in ER-positive patients who received adjuvant endocrine therapy (n = 1,216), low DNA-PKcs mRNA was significantly associated with poor BCSS (p = 0.009) (Fig. 3b) . In ER-negative tumours (n = 437), low DNAPKcs mRNA was significantly associated with poor BCSS (p = 0.041) (Fig. 3c) . In addition, in ER-negative patients who received adjuvant chemotherapy (n = 416), low DNA-PKcs mRNA remains significantly associated with poor BCSS (p = 0.017) (Fig. 3d) . Taken together, the protein and mRNA expression data provide evidence that DNA-PKcs may have prognostic and predictive significance in breast cancer patients.
Discussion
This is the first comprehensive study of DNA-PKcs expression in breast cancer. We found that low protein expression of DNA-PKcs was associated with adverse clinicopathological features including higher tumour grade, higher mitotic index, poorly differentiated and triple negative disease implying that impaired DNA-PKcs may be involved in breast cancer pathogenesis. Low DNA-PKcs was also linked to poor survival in univariate, as well as in multivariate analysis, suggesting prognostic significance in patients. Interestingly, in ER-positive tumours, the prognostic significance was retained. Moreover, in patients who received endocrine therapy, low DNA-PKcs/ER-positive tumours were associated with poor breast cancer-specific and disease-free survival compared to high DNA-PKcs/ Bold is statistically significant (p \ 0.05); BRCA1 breast cancer 1, early onset; HER2 human epidermal growth factor receptor 2; ER oestrogen receptor; PgR progesterone receptor; CK cytokeratin; Basal-like ER-, HER2-and positive expression of either CK5/6, CK14 or EGFR; Triple negative ER-/PgR-/HER2-ER-positive tumours that received endocrine therapy. Similarly, at the mRNA level, low DNA-PKcs mRNA expression was associated with poor survival in patients who received endocrine therapy. This new observation suggests that DNA-PKcs may predict response to endocrine therapy. Pre-clinically, the link between ER and DNA-PKcs has been reported [23] . DNA-PKcs was shown to phosphorylate and stabilise ER and promote ERdependent transcriptional activity. Moreover, oestrogen was also shown to induce DNA-PKcs expression in breast cancer cells in that study. Together, the authors suggested that reduced DNA-PKcs may be expected to attenuate oestrogen/ER-induced proliferation signalling in breast cancer cells [23] . However, the data presented in our study contradict the previous pre-clinical observation in that low DNA-PKcs was associated with aggressive breast cancer in our study implying that further mechanistic studies are required to investigate fully the functional link between DNA-PKcs and ER in breast cancer. Another possibility for the observed aggressive phenotype in human tumours is that low DNA-PKcs may be associated with, or reflect, genomic instability in cells. This is supported by the finding that low DNA-PKcs was significantly associated with low expression of several DNA repair proteins including BRCA1, XRCC1, SMUG1, APE1 and Polb. Impaired DNA repair and the associated genomic instability may promote accelerated accumulation of mutations, resulting in a 'mutator phenotype' characterised by aggressive clinical behaviour [24, 25] . The clinicopathological associations seen in breast cancer in our study also concur with a study of DNA-PKcs expression in 564 gastric cancers [26, 27] . Negative DNA-PKcs was found in 20.2 % of tumours and associated with aggressive tumours and poor survival. Interestingly, frameshift mutation of (A) 10 mononucleotide repeats in the DNA-PKcs gene was demonstrated in 24.3 % of gastric cancers which was associated with higher risk of lymph node metastasis in that study [26, 27] . Whether a similar mechanism also operates in breast cancer is currently unknown and could be an area for future investigation. Moreover, a previous study conducted extensive profiling of DNA-PKcs mRNA and protein levels across normal and cancerous tissues [28] . The A B C D authors demonstrated that DNA-PKcs protein was consistently low in breast cancer but no clinicopathological association data were reported. In normal tissues, although there are no significant changes at mRNA level, considerable variation was evident at the protein level implying that DNA-PKcs protein expression was likely regulated at the post-transcriptional or post-translational level [28] . Although the data presented in our study suggest that DNA-PKcs may regulated at the transcriptional level in breast cancer, whether additional mechanisms also operate is unknown. High-resolution deep sequencing of the DNA-PKcs gene in a cohort of breast cancer patients could provide further insight. In ovarian cancers, similarly, low DNA-PKcs was associated with stage and lymph node metastasis [29] . In contrast, in nasopharyngeal carcinoma, oesophageal cancer, colorectal cancer and lymphoid malignancies DNA-PKcs overexpression were associated with poor prognosis [12] . Taken together, the data suggest a complex role for DNA-Pkcs in different solid tumours. A surprising finding in the current study was that low DNA-PKcs mRNA in ER-negative tumours (including in patients who received adjuvant chemotherapy) was associated with poor survival and at the protein level, although there was trend, it did not reach significance. This is in [12] [13] [14] 15] . Although intriguing, the data concur with a recent report in a small cohort of breast cancers where high DNA-PKcs expression was associated with significant benefit from radiotherapy response in breast cancer patients [30] . The authors concluded that the role of proficient DNA-PKcs in p53-dependent pro-apoptotic response to cytotoxic therapy may have contributed to the observed effect [30] . However, in our study, we did not observe any associations with p53 expression in tumours. Further mechanistic studies are required to clarify the role of DNA-PKcs in chemotherapy and radiotherapy response in human tumours.
In conclusion, we have shown that altered DNA-PKcs expression may influence pathogenesis and have prognostic and predictive significance in breast cancer.
